Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  8/17/2015
Georgetown University
mi
from
Washington,
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 8/17/2015
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  8/17/2015
University of Chicago
mi
from
Chicago, IL
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 8/17/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  8/17/2015
Indiana University
mi
from
Indianapolis, IN
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 8/17/2015
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  8/17/2015
John Hopkins University
mi
from
Baltimore, MD
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 8/17/2015
John Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  8/17/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 8/17/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  8/17/2015
University of Michigan
mi
from
Ann Arbor, MI
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 8/17/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  8/17/2015
Memorial Sloan-Kettering Cancer Center
mi
from
NYC, NY
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 8/17/2015
Memorial Sloan-Kettering Cancer Center
mi
from
NYC, NY
Click here to add this to my saved trials
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  8/17/2015
University of North Carolina
mi
from
Charlotte, NC
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 8/17/2015
University of North Carolina
mi
from
Charlotte, NC
Click here to add this to my saved trials
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  8/17/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 8/17/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  8/17/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 8/17/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  8/17/2015
Baylor Breast Center
mi
from
Houston, TX
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 8/17/2015
Baylor Breast Center
mi
from
Houston, TX
Click here to add this to my saved trials
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  8/17/2015
Univ of Washington
mi
from
Seattle, WA
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 8/17/2015
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  8/17/2015
University of Alabama
mi
from
Birmingham, AL
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 8/17/2015
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  8/17/2015
University of California at San Francisco
mi
from
San Francisco, CA
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 8/17/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  8/17/2015
Emory University
mi
from
Atlanta, GA
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 8/17/2015
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  8/17/2015
The Mayo Clinic
mi
from
Rochester, MN
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 8/17/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases
Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases
Status: Enrolling
Updated:  8/17/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases
Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases
Status: Enrolling
Updated: 8/17/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Northshore University Health System, Kellogg Cancer Center
mi
from
Evanston, IL
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Northshore University Health System, Kellogg Cancer Center
mi
from
Evanston, IL
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
IN Onc/Hem Associates
mi
from
Indianapolis, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
IN Onc/Hem Associates
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Community Regional Cancer Center
mi
from
Indianapolis, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Community Regional Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Horizon Oncology Center
mi
from
Lafayette, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Horizon Oncology Center
mi
from
Lafayette, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Medical Consultants, P.C.
mi
from
Muncie, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Medical Consultants, P.C.
mi
from
Muncie, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Monroe Medical Associates
mi
from
Munster, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Monroe Medical Associates
mi
from
Munster, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Providence Medical Group
mi
from
Terre Haute, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Providence Medical Group
mi
from
Terre Haute, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Siteman Cancer Center
mi
from
St. Louis, MO
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Hematology Oncology Associates S.J., P.A.
mi
from
Mt. Holly, NJ
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Hematology Oncology Associates S.J., P.A.
mi
from
Mt. Holly, NJ
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Providence Portland Medical Center
mi
from
Portland, OR
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Pennsylvania Oncology Hematology Associates
mi
from
Philadelphia, PA
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Pennsylvania Oncology Hematology Associates
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Fox Chase Cancer Center Extramural Research Program
mi
from
Rockledge, PA
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Fox Chase Cancer Center Extramural Research Program
mi
from
Rockledge, PA
Click here to add this to my saved trials
Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer
Prospective Phase II Randomized Trial of Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer
Status: Enrolling
Updated:  8/17/2015
University of Michigan
mi
from
Ann Arbor, MI
Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer
Prospective Phase II Randomized Trial of Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer
Status: Enrolling
Updated: 8/17/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated:  8/18/2015
Andrew Thomas, MD
mi
from
Detroit, MI
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated: 8/18/2015
Andrew Thomas, MD
mi
from
Detroit, MI
Click here to add this to my saved trials
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated:  8/18/2015
Children's and Family Medical Clinic
mi
from
Allen Park, MI
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated: 8/18/2015
Children's and Family Medical Clinic
mi
from
Allen Park, MI
Click here to add this to my saved trials
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated:  8/18/2015
David Williams, MD
mi
from
Detroit, MI
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated: 8/18/2015
David Williams, MD
mi
from
Detroit, MI
Click here to add this to my saved trials
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated:  8/18/2015
Downriver Internists
mi
from
Allen Park, MI
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated: 8/18/2015
Downriver Internists
mi
from
Allen Park, MI
Click here to add this to my saved trials
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated:  8/18/2015
Dua Family Practice
mi
from
Canton, MI
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated: 8/18/2015
Dua Family Practice
mi
from
Canton, MI
Click here to add this to my saved trials
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated:  8/18/2015
George C. Hawrot, MD
mi
from
Dearborn, MI
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated: 8/18/2015
George C. Hawrot, MD
mi
from
Dearborn, MI
Click here to add this to my saved trials
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated:  8/18/2015
IPC - Livonia Internal Medicine
mi
from
Livonia, MI
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated: 8/18/2015
IPC - Livonia Internal Medicine
mi
from
Livonia, MI
Click here to add this to my saved trials
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated:  8/18/2015
Lonnie Joe Jr. MD
mi
from
Southfield, MI
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated: 8/18/2015
Lonnie Joe Jr. MD
mi
from
Southfield, MI
Click here to add this to my saved trials
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated:  8/18/2015
Mark W. Sawka, MD
mi
from
Woodhaven, MI
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated: 8/18/2015
Mark W. Sawka, MD
mi
from
Woodhaven, MI
Click here to add this to my saved trials
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated:  8/18/2015
Morang Chester Clinic
mi
from
Detroit, MI
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated: 8/18/2015
Morang Chester Clinic
mi
from
Detroit, MI
Click here to add this to my saved trials
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated:  8/18/2015
Rice Lanzilote & Egan
mi
from
Detroit, MI
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated: 8/18/2015
Rice Lanzilote & Egan
mi
from
Detroit, MI
Click here to add this to my saved trials
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated:  8/18/2015
University of Michigan Briarwood Family Medicine
mi
from
Ann Arbor, MI
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated: 8/18/2015
University of Michigan Briarwood Family Medicine
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated:  8/18/2015
University of Michigan Family Medicine at Corner Health Center
mi
from
Ypsilanti, MI
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated: 8/18/2015
University of Michigan Family Medicine at Corner Health Center
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated:  8/18/2015
University of Michigan Family Medicine at Domino's
mi
from
Ann Arbor, MI
Decision Aid to Technologically Enhance Shared Decision Making
Decision Aid to Technologically Enhance Shared Decision Making
Status: Enrolling
Updated: 8/18/2015
University of Michigan Family Medicine at Domino's
mi
from
Ann Arbor, MI
Click here to add this to my saved trials